Clinical Leader - Helping clinical research professionals connect and collaborate

Elsa's AI Model Migration: Technical, Compliance, And Regulatory Risks For Sponsors (Part 2)

In the second part of their series on Elsa AI model migration, Kimberly Chew, Esq., and Michael Yang, Esq., analyze the risks to compliance and data residency, as well as the integrity of the regulatory record.

GUEST COLUMNISTS

How Important Are Medical Monitors Under ICH E6(R3)?
Discover how medical monitor-led implementation of ICH E6(R3) outperforms operations-only models across six critical performance dimensions.
Old Habits, Communication Issues Still Stalling Site Budget Negotiations
Drawing from the 2025 SCRS Landscape Survey Report, Jimmy Bechtel and Ken Getz unpack how growing trial complexity, inconsistent fair market value benchmarks, and structural disconnects are reshaping site-sponsor relationships.
The Art Of Finding And Keeping The Right KOL
Learn from Incyclix CEO Patrick Roberts how the company identifies its KOLs, tailors engagement to their expertise, measures collaboration success, and sustains successful long-term partnerships.
What To Look For In Rare Disease Partnerships, With Origami's Beth Hoffman
Origami Therapeutics CEO Beth Hoffman shares how the company took both a measured and a gut-feeling approach to finding the right partner to supports its development of protein degraders for neurodegenerative diseases.
Lessons From Bringing A Novel T Cell Class For Autoimmune Diseases Into The Clinic
Tr1X Bio Co-founder and CEO David de Vries explains how moving Type 1 regulatory T Cell (Tr1) therapies into new indications reshapes every facet of first-in-human trial design.
PolarityBio Loosens I/E And Taps Many Provider Types To Reach More Patients
Discover how PolarityBio widened enrollment criteria and even developed improved delivery model to better serve investigators and patients in its Phase 3 trial for diabetic foot ulcers.
FDA's Elsa AI Switches From Claude To Gemini: What Sponsors Need To Know
Forced to cease using Anthropic's Claude for its Elsa generative AI assistant, the FDA is switching to Gemini. Legal experts Kimberly Chew, Esq., and Michael Yang, Esq., explain the implications for trade secrets and data security risks.
How The ACA Subsidy Lapse Could Hurt Clinical Trial Enrollment
The relationship between the Affordable Care Act (ACA) enhanced premium subsidies and clinical research isn’t widely understood, so consultant Devra Densmore is clearing things up, including how coverage loss could impact trial enrollment.

CLINICAL TRIAL WHITE PAPERS

How Sponsors Can Drive Success With Central eSource At Investigator Sites
Centralized eSource systems enable complex clinical trials to align with key regulatory frameworks, including ICH E6(R3), ICH E8(R1), and 21 CFR 312, to meet the highest standards of GCP.

Paper Vs ePRO: Clinical Data Collection Methods
7/16/2024

Patient-reported outcomes (PROs) assess patients' health without clinician interpretation. Traditional paper methods often result in missing data and quality issues, while electronic solutions enhance data accuracy and completeness.
Completed Clinical Trials, Terminations Both Rose In 2023
6/13/2024

This white paper highlights how the widespread growth in completed trials is coupled with higher success rates across multiple therapeutic areas, signaling the end of pandemic-related disruptions and infectious disease-related activity after three years of fluctuations.
Patient Diversity: Identifying Challenges, Opportunities, And Best Practices
4/10/2024

By listening to the voice of patient diversity and implementing FDA guidance measures, learn how stakeholders can improve trust, engagement, data reliability, patient outcomes, and promote public health.
A Guide To Digital Endpoints In Major Depressive Disorder
3/7/2025

The integration of digital health technologies (DHTs) in clinical trials for Major Depressive Disorder (MDD) is transforming how symptom severity and treatment efficacy are measured.
Continuous Cough Monitoring: Addressing Placebo Effects And Data Gaps
7/7/2025

Modernizing symptom monitoring is essential to improving clinical trial quality, and these tools deliver richer, more accurate data that can help close information gaps.

More Clinical Trial White Papers

CLINICAL TRIAL APP NOTES & CASE STUDIES

Tailored Approach Supports Bladder Cancer Breakthrough
3/5/2026

Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.
GxP Inventory Solution Delivers Real-Time Visibility, Operational Efficiency
12/10/2025

Explore how unified forecasting and GxP-level inventory control can streamline your clinical supply chain, reduce risk, and strengthen oversight across every trial you run.
Boosting Recruitment Strategy For Phase III Study In Ulcerative Colitis
6/10/2025

Learn about the successful execution of a challenging three-arm, randomized, placebo-controlled Phase 3 study in Ulcerative Colitis despite strict inclusion criteria and a limited patient pool.
Vaccine Trial Sees >90% eCOA Adherence
5/1/2024

Discover how we addressed vaccine trial challenges and drove remarkable success, achieving over 90% adherence to eCOA, ensuring active engagement from the trial participants, and yielding consistent, reliable trial data.
Advancing Neuromuscular Research with Digital Endpoints
1/20/2026

Explore cutting-edge digital measures that capture peak mobility and activity in real-world settings, offering meaningful insights into disease progression in neuromuscular disorders.
Enhance Access And Improve Retention In Rare Disease Trials With HTS
4/17/2025

Home Trial Support (HTS) provides a solution to improving participant recruitment and retention during musculoskeletal studies.

More Clinical Trial App Notes & Case Studies

NEWSLETTER ARCHIVE

More Newsletters

RECRUITMENT AND DIVERSITY

This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.

The Art Of Finding And Keeping The Right KOL

Learn from Incyclix CEO Patrick Roberts how the company identifies its KOLs, tailors engagement to their expertise, measures collaboration success, and sustains successful long-term partnerships.
PolarityBio Loosens I/E And Taps Many Provider Types To Reach More Patients

Discover how PolarityBio widened enrollment criteria and even developed improved delivery model to better serve investigators and patients in its Phase 3 trial for diabetic foot ulcers.
How The ACA Subsidy Lapse Could Hurt Clinical Trial Enrollment

The relationship between the Affordable Care Act (ACA) enhanced premium subsidies and clinical research isn’t widely understood, so consultant Devra Densmore is clearing things up, including how coverage loss could impact trial enrollment.

FOCUS ON PATIENTS

What To Look For In Rare Disease Partnerships, With Origami's Beth Hoffman

Origami Therapeutics CEO Beth Hoffman shares how the company took both a measured and a gut-feeling approach to finding the right partner to supports its development of protein degraders for neurodegenerative diseases.
PolarityBio Loosens I/E And Taps Many Provider Types To Reach More Patients

Discover how PolarityBio widened enrollment criteria and even developed improved delivery model to better serve investigators and patients in its Phase 3 trial for diabetic foot ulcers.
Patient-Powered Drug Trials Are Getting The FDA Greenlight

Patient- and parent-led drug development is on the rise, with the latest effort securing FDA clearance for a gene therapy trial. Yet, they are largely invisible. Buffalo Initiative plans to change that.